4.8 Article

Treatment of cancer pain

期刊

LANCET
卷 377, 期 9784, 页码 2236-2247

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)60236-5

关键词

-

资金

  1. CNSBio
  2. Covidien Mallinckrodt
  3. Grupo Ferrer
  4. King Pharmaceuticals
  5. ProStrakan Pharmaceuticals
  6. Purdue Pharrna
  7. Abbott Laboratories
  8. Ameritox
  9. Archimedes Pharmaceuticals
  10. Cephalon
  11. Endo Pharmaceuticals
  12. Forest Laboratories
  13. GW Pharma
  14. Meda Pharmaceuticals
  15. Ortho-McNeil Janssen
  16. Otsuka Pharma
  17. Purdue Pharma
  18. Tempur-Pedic Corp.

向作者/读者索取更多资源

In patients with active cancer, the management of chronic pain is an essential element in a comprehensive strategy for palliative care. This strategy emphasises multidimensional assessment and the coordinated use of treatments that together mitigate suffering and provide support to the patient and family. This review describes this framework, an approach to pain assessment, and widely accepted techniques to optimise the safety and effectiveness of opioid drugs and other treatments. The advances of recent decades suggest a future that includes increased evidence-based targeting of specific analgesic interventions within an individualised plan of care that is appropriate throughout the course of illness.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据